WO2006048264A3 - Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0 - Google Patents

Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0 Download PDF

Info

Publication number
WO2006048264A3
WO2006048264A3 PCT/EP2005/011730 EP2005011730W WO2006048264A3 WO 2006048264 A3 WO2006048264 A3 WO 2006048264A3 EP 2005011730 W EP2005011730 W EP 2005011730W WO 2006048264 A3 WO2006048264 A3 WO 2006048264A3
Authority
WO
WIPO (PCT)
Prior art keywords
leukemia
acute
bal
gene expression
aml
Prior art date
Application number
PCT/EP2005/011730
Other languages
English (en)
Other versions
WO2006048264A2 (fr
Inventor
Torsten Haferlach
Martin Dugas
Wolfgang Kern
Alexander Kohlmann
Susanne Schnittger
Claudia Schoch
Original Assignee
Roche Diagnostics Gmbh
Hoffmann La Roche
Torsten Haferlach
Martin Dugas
Wolfgang Kern
Alexander Kohlmann
Susanne Schnittger
Claudia Schoch
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roche Diagnostics Gmbh, Hoffmann La Roche, Torsten Haferlach, Martin Dugas, Wolfgang Kern, Alexander Kohlmann, Susanne Schnittger, Claudia Schoch filed Critical Roche Diagnostics Gmbh
Publication of WO2006048264A2 publication Critical patent/WO2006048264A2/fr
Publication of WO2006048264A3 publication Critical patent/WO2006048264A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/20—Supervised data analysis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Genetics & Genomics (AREA)
  • Theoretical Computer Science (AREA)
  • Data Mining & Analysis (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Bioethics (AREA)
  • Artificial Intelligence (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • Signal Processing (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des approches rapides et fiables permettant de détecter et de classer la leucémie. En plus de ces procédés de classification, l'invention concerne des trousses et systèmes correspondants.
PCT/EP2005/011730 2004-11-04 2005-11-03 Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0 WO2006048264A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62522104P 2004-11-04 2004-11-04
US60/625,221 2004-11-04

Publications (2)

Publication Number Publication Date
WO2006048264A2 WO2006048264A2 (fr) 2006-05-11
WO2006048264A3 true WO2006048264A3 (fr) 2006-09-21

Family

ID=35995492

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2005/011730 WO2006048264A2 (fr) 2004-11-04 2005-11-03 Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0

Country Status (1)

Country Link
WO (1) WO2006048264A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7085235B2 (ja) 2015-05-15 2022-06-16 国立大学法人高知大学 膵がん診断キット

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1993558B1 (fr) 2006-02-27 2014-07-30 The Regents of The University of California Composés oxystérols et hedgehog voie
WO2007137366A1 (fr) * 2006-05-31 2007-12-06 Telethon Institute For Child Health Research Indicateurs de diagnostic et de pronostic du cancer
BR102015007391B1 (pt) * 2015-04-01 2023-11-14 Instituto Hermes Pardini S.A. Biomarcadores para classificação de leucemias agudas
EP3548035A4 (fr) 2016-11-30 2020-07-22 Case Western Reserve University Combinaisons d'inhibiteurs de 15-pgdh avec des corcostéroïdes et/ou des inhibiteurs du tnf et leurs utilisations
US11718589B2 (en) 2017-02-06 2023-08-08 Case Western Reserve University Compositions and methods of modulating short-chain dehydrogenase

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies
WO2004091511A2 (fr) * 2003-04-10 2004-10-28 Genzyme Corporation Compositions et methodes de diagnostic et de traitement du cancer du poumon

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003039443A2 (fr) * 2001-11-05 2003-05-15 Deutsches Krebsforschungszentrum Nouveaux marqueurs genetiques pour leucemies
WO2004091511A2 (fr) * 2003-04-10 2004-10-28 Genzyme Corporation Compositions et methodes de diagnostic et de traitement du cancer du poumon

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BERREBI A ET AL: "RAB-1: a new monoclonal antibody to leukemic hairy cells.", LEUKEMIA RESEARCH. 1986, vol. 10, no. 9, 1986, pages 1071 - 1078, XP002373273, ISSN: 0145-2126 *
CATOVSKY D ET AL: "Heterogeneity of B-cell leukemias demonstrated by the monoclonal antibody FMC7.", BLOOD. AUG 1981, vol. 58, no. 2, August 1981 (1981-08-01), pages 406 - 408, XP002373274, ISSN: 0006-4971 *
HAFERLACH T ET AL: "The Diagnosis of 14 Specific Subtypes of Leukemia Is Possible Based on Gene Expression Profiles: A Study on 263 Patients with AML, ALL, CML, or CLL", BLOOD, W.B.SAUNDERS COMPANY, ORLANDO, FL, US, vol. 100, no. 11, 16 November 2002 (2002-11-16), pages 139A, XP002263227, ISSN: 0006-4971 *
KALEEM ZAHID ET AL: "Flow cytometric analysis of acute leukemias. Diagnostic utility and critical analysis of data.", ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE. JAN 2003, vol. 127, no. 1, January 2003 (2003-01-01), pages 42 - 48, XP009063952, ISSN: 1543-2165 *
PARTANEN J ET AL: "PUTATIVE TYROSINE KINASES EXPRESSED IN K-562 HUMAN LEUKEMIA CELLS", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 87, November 1990 (1990-11-01), pages 8913 - 8917, XP001061403, ISSN: 0027-8424 *
SIMONEAUX DENISE K ET AL: "The receptor tyrosine kinase-related gene (ryk) demonstrates lineage and stage-specific expression in hematopoietic cells", JOURNAL OF IMMUNOLOGY, vol. 154, no. 3, 1995, pages 1157 - 1166, XP009063614, ISSN: 0022-1767 *
WANG X C ET AL: "H-RYK, an unusual receptor kinase: Isolation and analysis of expression in ovarian cancer", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, vol. 2, no. 2, March 1996 (1996-03-01), pages 189 - 203, XP002955750, ISSN: 1076-1551 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7085235B2 (ja) 2015-05-15 2022-06-16 国立大学法人高知大学 膵がん診断キット

Also Published As

Publication number Publication date
WO2006048264A2 (fr) 2006-05-11

Similar Documents

Publication Publication Date Title
WO2006048262A3 (fr) Classification de la leucemie myeloblastique aigue
WO2008099241A3 (fr) Informations météorologiques sur un calendrier
WO2007067317A3 (fr) Sources d'ions, systemes et procedes
WO2005098445A3 (fr) Biomarqueurs de cancer du poumon
IN2012DN02302A (fr)
EP1651022A3 (fr) Support pour un composant
WO2004061410A3 (fr) Biomarqueurs seriques du cancer du poumon
WO2006048264A3 (fr) Etablissement de profils de l'expression genique de la leucemie lymphoblastique aigue (all), la leucemie aigue biphenotypique (bal) et la leucemie myeloide aigue (aml) m0
WO2004050839A3 (fr) Procedes et systemes de detection et d'analyse de variations de sequences bases sur la fragmentation
WO2007139603A3 (fr) Système de vérification et de criblage intégré
WO2005118878A3 (fr) Methodes de criblage de proliferation cellulaire ou de troubles neoplasiques
WO2006133018A3 (fr) Determination de localisation d'effleurement impliquant de multiples processus de localisation d'effleurement
WO2006043047A3 (fr) Systeme d'agregation spatiale permettant de fournir des informations
WO2006134390A3 (fr) Methode destinee a diagnostiquer une maladie neurodegenerative
WO2007047408A3 (fr) Application de signature promac
WO2007073554A3 (fr) Particules de copolymères séquencés
WO2005057166A3 (fr) Detection de proteines et de prions alteres de maniere conformationnelle
USD513774S1 (en) Hockey practice device
WO2004060302A3 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
WO2005065365A3 (fr) Systemes et procede pour l'amelioration esthetique
WO2004094667A3 (fr) Reactifs et methodes permettant de detecter le coronavirus responsable du syndrome respiratoire aigu severe
WO2007120156A3 (fr) Modeles animaux du syndrome du qt long congenital et leurs utilisations
WO2006048263A3 (fr) Profilage de l'expression genique dans la leucemie promyelocytique aigue
EP1758065A3 (fr) Procédé destiné à prévoir l'état du trafic dans un réseau routier et centrale de gestion du trafic
AU2003217639A1 (en) Detection by sliding template amplification

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05807889

Country of ref document: EP

Kind code of ref document: A2